Skip to content

US · DRUG · BIOTECHNOLOGY

Bright Minds Biosciences Inc. (DRUG) intrinsic value and stock valuation

$20.40as of 2026-11-21 · Mkt cap 782.97M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Bright Minds Biosciences Inc. DCF and intrinsic value

InvestorsCraft values DRUG with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from DRUG’s statements →

Bright Minds Biosciences Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology New York, NY 10013 brightmindsbio.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-12.23M
20192025
Free cash flow
-$-8.69M
20192025
Total equity
$82M+157.1% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-13.94M-$-2.82M-$-7.39M-$-14.98M-$-8.62M
Net income-$-12.23M-$-2.8M-$-7.37M-$-14.96M-$-8.65M
EPSd-$-1.78M-$-649.65K-$-1.98M-$-6.06M-$-4.83M
Operating cash flow-$-8.69M-$-1.85M-$-7.02M-$-13.59M-$-7.32M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-8.69M-$-1.85M-$-7.02M-$-13.59M-$-7.32M
Total assets$84.4M$6.1M$6.88M$12.1M$20M
Total debt$130K$120K$70K$140K$0.00
Net debt-$-82.78M-$-5.6M-$-6.67M-$-11.49M-$-19.76M
Total equity$82M$5.54M$6.6M$10.5M$19.4M
Cash and short-term investments$82.9M$5.72M$6.75M$11.6M$19.8M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$11.1M$1.18M$5M$12.2M$6.31M
Selling, general and administrative expenses$2.57M$1.45M$2.2M$2.55M$2.31M
Other expenses$290K$200K$190K$240K$0.00
Operating expenses$13.9M$2.82M$7.39M$15M$8.62M
Cost and expenses$13.9M$2.82M$7.39M$15M$8.62M
Interest income$1.52M$30K$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$80K$70K$70K$10K$8.62M
Ebitda-$-12.15M-$-2.73M-$-7.3M-$-14.96M-$-30K
Operating income-$-13.94M-$-2.82M-$-7.39M-$-14.98M-$-8.62M
Total other income/expenses, net$1.71M$20K$10K$10K-$-30K
Income before tax-$-12.23M-$-2.8M-$-7.37M-$-14.96M-$-8.65M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-12.23M-$-2.8M-$-7.37M-$-14.96M-$-8.65M
Weighted average shares outstanding$6.88M$4.31M$3.72M$2.47M$1.79M
Weighted average diluted shares outstanding$6.88M$4.31M$3.72M$2.47M$1.79M
Balance sheet
20252024202320222021
Cash and short-term investments$82.9M$5.72M$6.75M$11.6M$19.8M
Net receivables$410K$50K$40K$160K$110K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$84.3M$5.99M$6.81M$12M$20M
Property, plant and equipment, net$110K$120K$70K$140K$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$30K
Total non-current assets$110K$120K$70K$140K$0.00
Total assets$84.4M$6.1M$6.88M$12.1M$20M
Accounts payable$1.71M$410K$180K$1.25M$600K
Short-term debt$80K$80K$70K$70K$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$2.34M$530K$280K$1.47M$640K
Long-term debt$40K$40K$0.00$70K$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$40K$40K$0.00$70K$0.00
Capital lease obligations$130K$120K$70K$140K$0.00
Total liabilities$2.38M$570K$280K$1.54M$640K
Common stock$123.3M$35.4M$33.9M$32.2M$27.1M
Retained earnings-$-46.58M-$-34.35M-$-31.55M-$-24.17M-$-9.21M
Accumulated other comprehensive income (loss)$5.37M$4.01M$3.4M$2.48M$1.57M
Total equity$82M$5.54M$6.6M$10.5M$19.4M
Total investments$0.00$0.00$0.00$0.00$30K
Total debt$130K$120K$70K$140K$0.00
Net debt-$-82.78M-$-5.6M-$-6.67M-$-11.49M-$-19.76M
Cash flow statement
20252024202320222021
Net income-$-12.23M-$-2.8M-$-7.37M-$-14.96M-$-8.65M
Depreciation and amortization$80K$70K$70K$10K$0.00
Stock-based compensation$3.18M$840K$1.15M$880K$880K
Change in working capital$550K$40K-$-940K$720K$310K
Accounts receivable-$-360K-$-10K$120K-$-50K-$-110K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-8.69M-$-1.85M-$-7.02M-$-13.59M-$-7.32M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00$0.00$0.00$0.00
Common stock issued$86M$900K$1.22M$4.03M$27.7M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$85.6M$810K$2.19M$5.2M$26.1M
Net change in cash$77.2M-$-1.03M-$-4.88M-$-8.13M$19M
Cash at end of period$82.9M$5.72M$6.75M$11.6M$19.8M
Operating cash flow-$-8.69M-$-1.85M-$-7.02M-$-13.59M-$-7.32M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-8.69M-$-1.85M-$-7.02M-$-13.59M-$-7.32M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Bright Minds Biosciences Inc.

        Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.

        CEO
        Ian McDonald
        Employees
        26
        Beta
        0.10

        Explore

        Frequently asked questions

        What is the intrinsic value of Bright Minds Biosciences Inc. (DRUG)?

        InvestorsCraft does not currently publish an intrinsic value for DRUG. How the IC value is calculated.

        Is DRUG undervalued?

        InvestorsCraft does not publish an undervaluation signal for DRUG at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.